Skip to content

Released Nov 8, 2023, after the close

10-Q filed Nov 8, 2023, 39 days after period end · 0000950170-23-061148

Q3 2023 · 10-Q
Revenue$184.01M+61.4% vs Q3 2022−1.6% vs Q2 2023
Net Income-$28.86MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.77N/M vs Q3 2022N/M vs Q2 2023
Gross Profit$119,763,000+43.6%
Operating Income-$24,449,000N/M
Operating Cash Flowderived$477,000N/M
Free Cash Flowderived-$21,395,000N/M
Margins · derived
Gross margin65.1%−8.1 pt vs Q3 2022
Operating margin-13.3%−8.2 pt vs Q3 2022
Net margin-15.7%−6.3 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$184.01M$114.00M$112.43M$110.99M
Net Income-$28.86M-$10.72M-$2.17M$4.65M
EPS Diluted-$0.77-$0.53$0.11$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR